Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) (SZ Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) , closing price: 13.2 yuan) released the annual performance report on April 11, saying that the operating revenue in 2021 was about 6.365 billion yuan, a year-on-year increase of 19.38%; The net profit attributable to the shareholders of the listed company was about 241 million yuan, a year-on-year decrease of 76.49%; The basic earnings per share was 0.1641 yuan, a year-on-year decrease of 78.32%. It is proposed to pay a cash dividend of 0.35 yuan (including tax) for every 10 shares, no bonus shares and no increase.
From January to June 2021, Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) the composition of operating revenue is: pharmaceutical manufacturing accounts for 99.97%, and other industries account for 0.03%.
Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) ‘s general manager is Shan Yu, male, 62 years old, with a bachelor’s degree.
